Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

524 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy.
Locati LD, Piovesan A, Durante C, Bregni M, Castagna MG, Zovato S, Giusti M, Ibrahim T, Puxeddu E, Fedele G, Pellegriti G, Rinaldi G, Giuffrida D, Verderame F, Bertolini F, Bergamini C, Nervo A, Grani G, Rizzati S, Morelli S, Puliafito I, Elisei R. Locati LD, et al. Among authors: bergamini c. Eur J Cancer. 2019 Sep;118:35-40. doi: 10.1016/j.ejca.2019.05.031. Epub 2019 Jul 9. Eur J Cancer. 2019. PMID: 31299580
Previously irradiated areas spared from skin toxicity induced by cetuximab in six patients: implications for the administration of EGFR inhibitors in previously irradiated patients.
Bossi P, Liberatoscioli C, Bergamini C, Locati LD, Fava S, Rinaldi G, Orlandi E, Olmi P, Tagliabue E, Ménard S, Licitra L. Bossi P, et al. Among authors: bergamini c. Ann Oncol. 2007 Mar;18(3):601-2. doi: 10.1093/annonc/mdl409. Epub 2006 Oct 30. Ann Oncol. 2007. PMID: 17074970 Free article. No abstract available.
Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study.
Locati LD, Bossi P, Perrone F, Potepan P, Crippa F, Mariani L, Casieri P, Orsenigo M, Losa M, Bergamini C, Liberatoscioli C, Quattrone P, Calderone RG, Rinaldi G, Pilotti S, Licitra L. Locati LD, et al. Among authors: bergamini c. Oral Oncol. 2009 Jul;45(7):574-8. doi: 10.1016/j.oraloncology.2008.07.010. Epub 2008 Sep 18. Oral Oncol. 2009. PMID: 18804410 Clinical Trial.
Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs).
Locati LD, Perrone F, Losa M, Mela M, Casieri P, Orsenigo M, Cortelazzi B, Negri T, Tamborini E, Quattrone P, Bossi P, Rinaldi G, Bergamini C, Calderone RG, Liberatoscioli C, Licitra L. Locati LD, et al. Among authors: bergamini c. Oral Oncol. 2009 Nov;45(11):986-90. doi: 10.1016/j.oraloncology.2009.05.635. Epub 2009 Jul 1. Oral Oncol. 2009. PMID: 19574086
Docetaxel, cisplatin and 5-fluorouracil-based induction chemotherapy followed by intensity-modulated radiotherapy concurrent with cisplatin in locally advanced EBV-related nasopharyngeal cancer.
Bossi P, Orlandi E, Bergamini C, Locati LD, Granata R, Mirabile A, Parolini D, Franceschini M, Fallai C, Olmi P, Quattrone P, Potepan P, Gloghini A, Miceli R, Mattana F, Scaramellini G, Licitra L. Bossi P, et al. Among authors: bergamini c. Ann Oncol. 2011 Nov;22(11):2495-2500. doi: 10.1093/annonc/mdq783. Epub 2011 Mar 11. Ann Oncol. 2011. PMID: 21398385 Free article.
Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: an Italian validation study.
Granata R, Miceli R, Orlandi E, Perrone F, Cortelazzi B, Franceschini M, Locati LD, Bossi P, Bergamini C, Mirabile A, Mariani L, Olmi P, Scaramellini G, Potepan P, Quattrone P, Ang KK, Licitra L. Granata R, et al. Among authors: bergamini c. Ann Oncol. 2012 Jul;23(7):1832-7. doi: 10.1093/annonc/mdr544. Epub 2011 Nov 24. Ann Oncol. 2012. PMID: 22115925 Free article.
524 results